OBGYN Physician Office Laboratory (POL) Case Study
ENTITY BACKGROUND
A Women’s Health Physician Office Laboratory (POL) was previously partnered with another assay manufacturer known for offering low-cost molecular tests but lacking strong scientific credentials. Despite having an in-house lab, the practice saw limited provider adoption.
COMPETITIVE CONTEXT
The client transitioned away from the manufacturer due to low clinical engagement and poor alignment with provider needs.
CHALLENGE
The lab faced minimal utilization by its own providers. Key issues included:
a) The original assays were qualitative (positive/negative only), offering little clinical nuance.
b) The pathogens targeted by the tests did not reflect the most relevant concerns of the OBGYN providers.
Solution
OSPRI redesigned the assay menu to match what providers actually needed in their clinical workflows. Additionally, OSPRI introduced semi-quantitative results—allowing physicians to assess levels of infectivity and significance, therefore determining treatment relevance with greater confidence.
Results
Monthly test volume increased purely due to the clinical relevance and improved utility of the new testing platform.500 TO 1,846
Financial Impact Summary
$250 | Avg. Reimbursement Per Test |
$337k | Approx. New Monthly Income |
$2.4M | Annualized EBITDA lift |
Hospital Case Study
ENTITY BACKGROUND
A large regional hospital system with 28 locations engaged OSPRI to design and build a high complexity molecular laboratory as part of an offensive growth strategy—aimed at expanding clinical capabilities and recapturing testing volume across its provider network.
COMPETITIVE CONTEXT
OSPRI was selected over multiple national diagnostic vendors and platform manufacturers, replacing the hospital’s existing closed-system PCR setup.
CHALLENGE
Although the hospital operated a basic PCR lab, it relied on “closed-system” technology limited to 3–5 pathogen targets far fewer than the 10–50 targets providers typically require. As a result, none of the hospital’s 2,500 affiliated and employed providers used the internal lab for outpatient testing. Nearly all PCR orders were being outsourced to an external reference lab, resulting in significant revenue leakage.
Solution
OSPRI developed, validated, and launched a fully-integrated, high-throughput PCR lab within the hospital system, converting 16k monthly in-patient tests to the new platform. Simultaneously, OSPRI helped launch a network-wide campaign to redirect outpatient PCR testing to the in-house lab.
Results
With clinically aligned assays and scalable infrastructure, the hospital is now positioned to centralize molecular testing internally, reduce turnaround times, and capture significant revenue from both inpatient and outpatient testing.
Financial Impact Summary
The projected annual EBITDA for the hospital system, based on conservative volume and reimbursement assumptions.$25M | Project Annual EBITDA |
Independent Clinical Laboratory(ICL) Case Study
ENTITY BACKGROUND
A high-throughput clinical laboratory processes approximately 180 patient samples per day. To meet this volume, their current workflow requires 17–18 thermal cycles per day, placing a significant strain on personnel, equipment, and consumables.
COMPETITIVE CONTEXT
The lab was previously operating on a platform provided by a long-standing diagnostic vendor, whose assay design had gone largely unchanged despite clear workflow inefficiencies.
CHALLENGE
The lab faced a daily operational dilemma:
1. Run all samples immediately and waste assays due to batch based limitations, resulting in significant hidden costs.
2. Hold samples until the next day to avoid waste, thereby delaying turnaround time and compromising service levels. This created a recurring trade-off between cost-efficiency and clinical speed.
Solution
OSPRI conducted a mathematical and operational analysis of the lab’s current assay and throughput model. By optimizing assay design and thermal cycling strategy, OSPRI demonstrated the lab could process the entire daily volume using just 6 thermal cycles—with zero wasted assays and no need to delay samples.
Workflow Impact Summary
18 TO 6 | Daily-Thermal Cycles |
100% | Of Assay Waste Eliminated |
100% | Same-Day Samples Processed |
